Browse the evidence

Adiponectin, an anti-inflammatory adipokine, improves insulin sensitivity by activating AMPK to enhance fatty acid oxidation and glucose uptake, but its levels are decreased in obesity due to suppression by inflammatory signals.

Adiponectin helps muscles use glucose and fat for energy. In obesity, this protective hormone is suppressed by inflammation. Restoring adiponectin levels (e.g., through weight loss or exercise) can help restore insulin sensitivity.

Lipodystrophy (loss of adipose tissue) causes the same metabolic syndrome and insulin resistance as obesity, proving that adipose tissue is essential for metabolic health.

Do not aim for extremely low body fat levels. Your body needs adipose tissue to store energy safely. If you lose too much fat, it can lead to insulin resistance and metabolic syndrome, similar to obesity. Maintain a healthy amount of fat, particularly subcutaneous fat, to support metabolic health.

Increased intramyocellular ceramide content in obese insulin-resistant humans is associated with impaired insulin-stimulated Akt phosphorylation and reduced glucose uptake.

In obese individuals with insulin resistance, high levels of a specific fat molecule called ceramide in muscle cells interfere with insulin's ability to signal for glucose uptake. This suggests that managing intramuscular lipid composition, particularly ceramides, is crucial for improving insulin sensitivity, potentially more so than just total fat mass.

Biologic mechanisms linking physical activity, sedentary behavior, and obesity to cancer risk include effects on endogenous insulin sensitivity, chronic sex steroids, metabolic hormones, and inflammation.

Understanding that exercise and weight management affect hormones and inflammation helps explain why these lifestyle factors prevent cancer.

Long-term transdermal testosterone gel (AndroGel) treatment in hypogonadal men maintains beneficial effects on sexual function, mood, lean body mass, fat mass, and bone mineral density without significant increases in muscle strength.

If you are a hypogonadal man, long-term use of testosterone gel (5-10g daily) effectively restores sexual function, improves mood, increases lean mass, and reduces fat mass. These benefits are maintained over several years. However, do not expect significant gains in muscle strength despite the increase in lean mass. Regular monitoring of prostate health and blood counts is essential to manage safety risks.

Pericardial fat is specifically associated with myocardial infarction and coronary heart disease, suggesting a local paracrine effect on coronary arteries, whereas VAT is more strongly associated with stroke, suggesting a systemic effect.

Targeting specific fat depots may offer targeted cardiovascular protection. Reducing visceral abdominal fat through diet and exercise can lower stroke risk, while managing overall adiposity may help reduce pericardial fat, potentially lowering the risk of myocardial infarction. A holistic approach to metabolic health addresses both systemic and local inflammatory risks.

Obesity disrupts female fertility through multiple mechanisms including HPO axis deregulation, adipokine-mediated inflammation, and oocyte quality reduction, leading to anovulation and reduced IVF success rates.

If you are obese, your fertility is likely compromised even if your periods are regular. This is due to hormonal imbalances and inflammation affecting egg quality and implantation. Weight loss through lifestyle modification is proven to restore menstrual cyclicity and ovulation, improving conception chances.

Adipokines (leptin, adiponectin, resistin, etc.) released by adipose tissue in obesity directly interfere with ovarian function, insulin sensitivity, and endometrial receptivity, contributing to infertility.

Your fat tissue is not just storage; it acts as an endocrine organ releasing hormones that disrupt your reproductive system. This is why weight loss helps.

Peripheral endocannabinoid system overactivity in adipose and pancreatic tissues directly contributes to obesity-related metabolic dysregulation, including hyperinsulinemia, lipogenesis, and hypoadiponectinemia, independent of central appetite control.

This research suggests that obesity involves a dysregulated signaling system in fat and pancreatic cells that promotes fat storage and insulin resistance, regardless of how much you eat. While this paper does not prescribe a specific diet or exercise routine, it highlights that targeting these peripheral pathways (e.g., via medications like rimonabant, though withdrawn) addresses the root hormonal drivers of metabolic syndrome. For current practice, this underscores the importance of interventions that improve insulin sensitivity and reduce visceral fat, as these may help normalize endocannabinoid signaling.

The DunedinPoAm DNA methylation algorithm accurately quantifies the pace of biological aging (rate of decline in system integrity) rather than just chronological age, serving as a valid surrogate endpoint for testing interventions that slow aging.

This paper introduces a blood test (DunedinPoAm) that measures how fast your body is aging biologically, distinct from your chronological age. It is currently a research tool used to validate interventions like caloric restriction (CALERIE trial) that slow aging. For now, it is not a commercial consumer product, but it validates that slowing biological aging is measurable and that interventions like calorie restriction can impact this rate.

Genetic predisposition for longer habitual sleep duration is causally linked to an increased risk of schizophrenia, and conversely, genetic risk for schizophrenia causes longer sleep duration, indicating a bidirectional causal relationship.

If you naturally sleep longer than average (e.g., >8-9 hours), it may be partly due to your genetics. This paper suggests a causal link between longer sleep and higher schizophrenia risk, but also that schizophrenia risk drives longer sleep. Focus on overall mental health monitoring rather than trying to force shorter sleep, as sleep duration is largely genetically fixed.

Inhibition of the MAP kinase pathway (via MEK inhibition) enhances skeletal muscle myoblast differentiation, whereas activation of the PI 3-kinase/p70S6k pathway is essential for IGF-stimulated differentiation.

This research suggests that muscle cell differentiation is not simply the absence of growth signals. Instead, it requires a specific signal (PI 3-kinase pathway) to proceed, while the growth signal (MAPK pathway) actively suppresses it. For muscle building contexts, this implies that simply stopping cell division is not enough; specific molecular pathways must be activated to trigger the structural changes of differentiation.

In obese adults, excess visceral fat and insulin resistance are independently associated with incident prediabetes and type 2 diabetes, whereas general adiposity markers (BMI, total body fat, abdominal subcutaneous fat) are not.

If you are obese, your total weight or BMI is not the best predictor of your diabetes risk. Instead, focus on markers of 'dysfunctional adiposity': visceral fat (belly fat), insulin resistance, and liver fat. These specific factors drive the transition to prediabetes and diabetes, whereas general fat mass does not. Monitoring visceral fat and insulin sensitivity is more clinically relevant than tracking BMI alone.

Pancreatic beta cells are uniquely susceptible to oxidative stress and hypoxia-induced dysfunction because they express unusually low levels of antioxidant defense enzymes (such as catalase) while maintaining high metabolic activity and ROS production.

Beta cells are naturally vulnerable to damage from high blood sugar and fat levels because they lack strong internal antioxidant defenses. This vulnerability is a key reason why Type 2 Diabetes develops when metabolic demands are high. While oxidative stress contributes to this damage, simply taking antioxidant supplements has not been proven to prevent or treat diabetes in humans. The primary focus should remain on managing the root causes: reducing nutrient oversupply through diet and lifestyle changes to lower the metabolic load on beta cells.

Reactive Oxygen Species (ROS) are not merely toxic byproducts but are necessary for normal glucose-stimulated insulin secretion in pancreatic beta cells.

Your beta cells use small amounts of oxidative stress as a signal to release insulin when you eat. This is a normal and necessary part of how your body regulates blood sugar. While chronic, high levels of oxidative stress from obesity and high blood sugar damage beta cells, completely eliminating this signaling pathway would impair your ability to secrete insulin. The goal is metabolic balance, not the total elimination of oxidative processes.

Hypoxia (low oxygen) in pancreatic islets, particularly in the core of transplanted islets or in obese individuals, contributes to beta-cell apoptosis and dysfunction by stabilizing Hypoxia-Inducible Factors (HIFs).

For patients undergoing islet transplantation, oxygen levels are critical. Islets transplanted into the liver often suffer from hypoxia in their core, leading to cell death. Medical strategies are being developed to protect these cells from oxygen deprivation, such as using antioxidants or choosing better transplantation sites, to improve the chances of long-term insulin independence.

Bacterial translocation of lipopolysaccharide (LPS) from the gut to the bloodstream (metabolic endotoxemia) due to increased intestinal permeability ('leaky gut') triggers systemic inflammation and insulin resistance.

Avoid excessive intake of saturated fats and refined sugars, which are linked to increased intestinal permeability and higher circulating LPS levels, thereby reducing the risk of inflammation-driven insulin resistance.

High levels of dietary trypsin inhibitors in raw soybeans and legumes significantly reduce protein and amino acid digestibility (by up to 50%) and protein quality (by up to 100%) in animal models due to pancreatic hypertrophy and endogenous amino acid loss.

If you eat soybeans, kidney beans, or other legumes, ensure they are properly cooked (boiled, autoclaved, or roasted). Raw or under-processed legumes contain trypsin inhibitors that can block protein digestion and reduce nutrient absorption by up to 50%. Processing inactivates these inhibitors, making the protein much more available to your body.

Tannins in sorghum and legumes reduce protein and amino acid digestibility by binding to proteins and precipitating them, with reductions of up to 23% observed in animal models.

If your diet relies heavily on sorghum or tannin-rich legumes like fababean, be aware that tannins can reduce protein absorption by up to 23%. Processing methods like dehulling, soaking, or germination can help reduce tannin levels and improve protein digestibility.

Acarbose treatment reduces the risk of myocardial infarction and any cardiovascular events in type 2 diabetic patients.

If you have type 2 diabetes, acarbose, taken three times daily with meals, may significantly lower your risk of heart attacks and other cardiovascular events. This benefit appears even if you are already taking other heart medications. The drug works by reducing the spike in blood sugar after eating, which may protect your blood vessels.

Initiating supplemental parenteral nutrition (SPN) within the first week of ICU admission provides no clinically important benefit compared to enteral nutrition (EN) alone.

Do not start supplemental parenteral nutrition (SPN) in the first week of ICU stay for average critically ill patients. Focus on enteral nutrition (EN) tolerance. Consider SPN only after day 7 if EN remains insufficient, especially for malnourished patients.

Providing similar energy intake via parenteral nutrition (PN) as compared to enteral nutrition (EN) in the first week of critical illness results in similar clinical outcomes.

If a critically ill patient cannot tolerate enteral nutrition (EN), parenteral nutrition (PN) is an acceptable alternative. Ensure similar energy intake and monitor for glycemic control and catheter-related infections. Cost and convenience may guide the choice.

Rosiglitazone treatment (4 mg twice daily for 10-12 weeks) improves whole-body insulin sensitivity in patients with type 2 diabetes by enhancing the insulin sensitivity of peripheral adipocytes, which reduces plasma fatty acid concentrations and redistributes triglycerides from the liver and muscle to subcutaneous adipose tissue.

For patients with type 2 diabetes, rosiglitazone (4mg twice daily) significantly improves how the body uses insulin. It works by making fat cells more sensitive to insulin, which lowers fatty acids in the blood and moves stored fat out of the liver and muscles into safe fat stores. This improves blood sugar control without necessarily changing body weight or intramuscular fat levels.

Metabolically healthy obesity (MHO) is not a distinct protective phenotype but rather a transient state characterized by fewer metabolic abnormalities than metabolically unhealthy obesity (MUO), with a high likelihood of progressing to MUO over time.

Do not rely on the label 'metabolically healthy' to ignore metabolic risks. Even if you do not have high blood pressure or diabetes, you may still have insulin resistance or liver fat. Focus on improving insulin sensitivity through diet and activity rather than assuming your current state is safe.